• Skip to main content

Parkinson’s Treatment Report

www.ParkinsonsTreatmentReport.com

DNL151

Study to Evaluate DNL151 in Subjects With Parkinson’s Disease

September 18, 2019

https://clinicaltrials.gov/ct2/show/NCT04056689?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=07%2F31%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Study to Evaluate DNL151 in Subjects With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: DNL151 low dose;   Drug: DNL151 high dose;   Drug: Placebo
Sponsor:   Denali Therapeutics Inc.
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04056689

FIRST POSTED:
Wed, 14 Aug 2019 12:00:00 EDT

LAST UPDATE POSTED:
08/14/19 07:51AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04056689?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=07%2F31%2F2019&lupd_d=14&sort=nwst

Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease

September 3, 2019

https://www.globenewswire.com/news-release/2019/09/04/1910858/0/en/Denali-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1b-Study-of-DNL151-for-Parkinson-s-Disease-and-Launch-of-Its-Engage-Parkinson-s-Website.html

Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage Parkinson’s Website

Powered by Urgent Research

Copyright © 2025 Urgent Research